Melanoma trials recruiting in Texas

All Melanoma trials nationally

Cities in Texas

Recruiting trials in Texas

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
  NCT04370587 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
  NCT06022029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
  NCT06413680 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
  NCT07317505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Fort Worth, Houston
• A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  NCT06956690 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, San Antonio
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · Texas: Dallas, Houston
• A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
  NCT05970497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: El Paso, Houston, The Woodlands
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Bedford, Dallas, Fort Worth
• A Study of BI 3810944 in Patients With Advanced Cancer
  NCT07224425 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
  NCT06594991 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of IBI363 in Subjects with Advanced Solid Malignancies
  NCT06281678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Irving, San Antonio
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
  NCT02332668 · Phase: Phase 1, Phase 2 · Ages: 6 Months to 17 Years · Sex: All (male and female) · Texas: Dallas
• A Study of VET3-TGI in Patients With Solid Tumors
  NCT06444815 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
  NCT06880549 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: San Antonio
• A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
  NCT06805825 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
  NCT07749586 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: San Antonio
• A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  NCT04913285 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Amarillo, Dallas, Pearland
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
  NCT06326411 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
  NCT05538130 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · Texas: Houston
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
  NCT05355701 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · Texas: San Antonio
• ACTengine® IMA203 Combined With mRNA-4203
  NCT06946225 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
  NCT04771520 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
  NCT05026983 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• BostonGene and Exigent Genomic INsight Study
  NCT06272864 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Texas: Amarillo, Bryan, Houston, Laredo
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
  NCT04693377 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Anderson, Houston
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Texas: Dallas
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
  NCT07288112 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• Dabrafenib and/or Trametinib Rollover Study
  NCT03340506 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Texas: Dallas
• Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
  NCT03567889 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
  NCT04038619 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
  NCT05053555 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years and older · Sex: All (male and female) · Texas: Houston
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
  NCT05039801 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• IDOV-Immune for Advanced Solid Tumors
  NCT06910657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
  NCT06400550 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study
  NCT06887205 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Intratumoral N17350 in Advanced Solid Tumors
  NCT07339176 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
  NCT03941756 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio
• Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
  NCT01772771 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Texas: Houston
• Neoadjuvant Darovasertib in Primary Uveal Melanoma
  NCT07015190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston
• Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
  NCT06548789 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
  NCT04594187 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  NCT05059444 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Edinburg, Forth Worth, San Antonio
• Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
  NCT06660420 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
  NCT06249048 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
  NCT06683755 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
  NCT05704647 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
  NCT06545682 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
  NCT06466434 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
  NCT07327489 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Forth Worth, Temple
• Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
  NCT05546827 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Texas: Amarillo, Austin, Corpus Christi, Dallas
• Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
  NCT04778449 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
  NCT03819296 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Texas: Dallas, Houston, Temple
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors
  NCT06060613 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Sample Collection for Ongoing Research and Product Evaluation Study
  NCT07318051 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
  NCT07287917 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, Laredo
• Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
  NCT05267626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Houston, San Antonio
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
  NCT03093909 · Phase: Phase 1 · Ages: 12 Years to 50 Years · Sex: All (male and female) · Texas: Houston
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
  NCT03947385 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
  NCT04198766 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, El Paso, San Antonio, The Woodlands
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, Lewisville
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, San Antonio
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Fort Worth, Houston, Paris
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
  NCT05549297 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · Texas: Houston
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Conroe, Houston, League City, San Antonio
• Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
  NCT04751396 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
  NCT06264180 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
  NCT04474301 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Texas: Houston